| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Inc., Gaithersburg, Maryland 20878 [P. G. K., S. U. S., C. R. K.], and Laboratory of Cellular and Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 [P. P. D.]
Amplification and/or overexpression of the erbB-2 gene have been demonstrated in 20–30% of adenocarcinomas of the breast, ovary, lung, and stomach and are associated with aggressive clinical course and poor prognosis. Interference with erbB-2 function by the use of monoclonal antibodies is a promising approach to the treatment of these diseases. In this study we demonstrate that a combination of two anti-erbB-2-specific antibodies inhibited the growth of human gastric tumor cells in vitro. This combination antibody therapy also inhibited the growth of human tumor cell lines growing as xenografts in nude mice and was able to dramatically reduce established tumors. This is the first reported observation of tumor regression induced by anti-erbB-2 monoclonal antibodies. Treatment was not curative in that tumors regrew after 6 weeks. Treatment with either single antibody alone did not inhibit cell growth or tumor formation. Pulse chase and tyrosine kinase activity experiments were used to investigate the activity of the erbB-2 gene product (gp185erbB-2). The formation of complexes by two antibodies was found to interfere with receptor function and mimic some properties of a typical receptor ligand. Selective interference of the erbB-2 receptor by combination antibody therapy may be advantageous for the treatment of human cancers.
1 Supported by Grant 2 R44 CA50077-02 from the Department of Health and Human Services.
2 To whom requests for reprints should be addressed, at Molecular Oncology, Inc., 19 Firstfield Road, Gaithersburg, MD 20878.
Received 8/29/91. Accepted 3/11/92.
This article has been cited by other articles:
|
|
 |
|
  C. C. Portera, J. M. Walshe, D. R. Rosing, N. Denduluri, A. W. Berman, U. Vatas, M. Velarde, C. K. Chow, S. M. Steinberg, D. Nguyen, et al. Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2710 - 2716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kunii, L. Davis, J. Gorenstein, H. Hatch, M. Yashiro, A. Di Bacco, C. Elbi, and B. Lutterbach FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival Cancer Res., April 1, 2008; 68(7): 2340 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Emanuel, T. V. Hughes, M. Adams, C. A. Rugg, A. Fuentes-Pesquera, P. J. Connolly, N. Pandey, S. Moreno-Mazza, J. Butler, V. Borowski, et al. Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors Mol. Pharmacol., February 1, 2008; 73(2): 338 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Ritter, M. Perez-Torres, C. Rinehart, M. Guix, T. Dugger, J. A. Engelman, and C. L. Arteaga Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network Clin. Cancer Res., August 15, 2007; 13(16): 4909 - 4919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Wong, F. Y. Lee, C. Yu, F. R. Luo, S. Oppenheimer, H. Zhang, R. A. Smykla, H. Mastalerz, B. E. Fink, J. T. Hunt, et al. Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling. Clin. Cancer Res., October 15, 2006; 12(20): 6186 - 6193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kimura, T. Sawada, M. Komatsu, M. Inoue, K. Muguruma, T. Nishihara, Y. Yamashita, N. Yamada, M. Ohira, and K. Hirakawa Antitumor Effect of Trastuzumab for Pancreatic Cancer with High HER-2 Expression and Enhancement of Effect by Combined Therapy with Gemcitabine. Clin. Cancer Res., August 15, 2006; 12(16): 4925 - 4932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Vallera, D. A. Todhunter, D. W. Kuroki, Y. Shu, A. Sicheneder, and H. Chen A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma Clin. Cancer Res., May 15, 2005; 11(10): 3879 - 3888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Friedman, A. Rinon, B. Schechter, L. Lyass, S. Lavi, S. S. Bacus, M. Sela, and Y. Yarden Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy PNAS, February 8, 2005; 102(6): 1915 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-D. Way, M.-C. Kao, and J.-K. Lin Apigenin Induces Apoptosis through Proteasomal Degradation of HER2/neu in HER2/neu-overexpressing Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt-dependent Pathway J. Biol. Chem., February 6, 2004; 279(6): 4479 - 4489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Dakappagari, J. Pyles, R. Parihar, W. E. Carson, D. C. Young, and P. T. P. Kaumaya A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses J. Immunol., April 15, 2003; 170(8): 4242 - 4253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nahta, G. N. Hortobagyi, and F. J. Esteva Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention Oncologist, February 1, 2003; 8(1): 5 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Frankel New HER2-directed Therapies for Breast Cancer.: Commentary re: C. I. Spiridon et al., Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity. Clin. Cancer Res., 8: 1720-1730, 2002. Clin. Cancer Res., June 1, 2002; 8(6): 1699 - 1701. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ohta, Y. Tokuda, Y. Suzuki, M. Kubota, T. Watanabe, H. Fujii, Y. Sasaki, T. Niwa, H. Makuuchi, and T. Tajima A Case with HER2-overexpressing Breast Cancer Completely Responded to Humanized anti-HER2 Monoclonal Antibody Jpn. J. Clin. Oncol., November 1, 2001; 31(11): 553 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Di Carlo, G. Forni, P. Lollini, M. P. Colombo, A. Modesti, and P. Musiani The intriguing role of polymorphonuclear neutrophils in antitumor reactions Blood, January 15, 2001; 97(2): 339 - 345. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mandler, C. Wu, E. A. Sausville, A. J. Roettinger, D. J. Newman, D. K. Ho, C. R. King, D. Yang, M. E. Lippman, N. F. Landolfi, et al. Immunoconjugates of Geldanamycin and Anti-HER2 Monoclonal Antibodies: Antiproliferative Activity on Human Breast Carcinoma Cell Lines J Natl Cancer Inst, October 4, 2000; 92(19): 1573 - 1581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. N. Klapper, H. Waterman, M. Sela, and Y. Yarden Tumor-inhibitory Antibodies to HER-2/ErbB-2 May Act by Recruiting c-Cbl and Enhancing Ubiquitination of HER-2 Cancer Res., July 1, 2000; 60(13): 3384 - 3388. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. Visco, R. Bei, E. Moriconi, W. Gianni, M. H. Kraus, and R. Muraro ErbB2 Immune Response in Breast Cancer Patients with Soluble Receptor Ectodomain Am. J. Pathol., April 1, 2000; 156(4): 1417 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Pai-Scherf, J. Villa, D. Pearson, T. Watson, E. Liu, M. C. Willingham, and I. Pastan Hepatotoxicity in Cancer Patients Receiving erb-38, a Recombinant Immunotoxin That Targets the erbB2 Receptor Clin. Cancer Res., September 1, 1999; 5(9): 2311 - 2315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Kindzelskii and H. R. Petty Early Membrane Rupture Events During Neutrophil-Mediated Antibody-Dependent Tumor Cell Cytolysis J. Immunol., March 15, 1999; 162(6): 3188 - 3192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A Underwood, J M Bartlett, and T G Cooke An improved method for semiquantification of gene amplification from archival material. Genome Res., December 1, 1994; 4(3): 178 - 184. [Abstract] [PDF]
|
|
|
|
|
|
G. Levkowitz, S. Oved, L. N. Klapper, D. Harari, S. Lavi, M. Sela, and Y. Yarden c-Cbl Is a Suppressor of the Neu Oncogene J. Biol. Chem., November 3, 2000; 275(45): 35532 - 35539. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
